Pharmacotherapy Update in Rheumatoid Arthritis and Osteoarthritis
Track:
Education Sessions (CE)
Program Code: 229-L01
Date: Tuesday, December 6, 2011
Time: 9:00 AM to 11:00 AM EST
Location:
Room 354, Level 3
PRESENTER(S):
Click the plus sign to see more detailed information about each speaker.
Eric MacLaughlin, PharmD, BCPS, Associate Professor and Division Head of Adult Medicine, Texas Tech School of Pharmacy
Eric MacLaughlin, Pharm.D., FCCP, BCPS is an Associate Professor and Division Head of Adult Medicine, Department of Pharmacy Practice at Texas Tech School of Pharmacy. He is also a Clinical Pharmacist with the Department of Family Medicine at Texas Tech School of Medicine. He received his B.S. in Pharmacy from Albany College of Pharmacy, Pharm.D. from the Medical University of South Carolina, and completed a Primary Care Specialty Residency at the University of Colorado. His practice interests include family medicine and outpatient geriatrics. Research interests include the treatment of hypertension, screening and treatment of osteoporosis, and pharmacy education.
Dr. Saseen is an Associate Professor of Clinical Pharmacy and Family Medicine at the University of Colorado Denver. He is a Board Certified Pharmacotherapy Specialist with added qualifications in cardiology, is certified as a Clinical Lipid Specialist, and is a Fellow of the American College of Clinical Pharmacy. Dr. Saseen received both his B.S. pharmacy degree and PharmD degree from the State University of New York at Buffalo and then completed an ambulatory care research fellowship at the University of Illinois at Chicago. In his current position, Dr. Saseen practices as a clinical pharmacy specialist at University of Colorado’s Family Medicine Center, and educates pharmacy and medical students. His research and other scholarly endeavors focus on cardiovascular pharmacotherapy. Dr. Saseen is on the board of regents for the American College of Clinical Pharmacy, is a member of the Board of Directors for the National Lipid Association’s Accreditation Council for Clinical Lipidology, and is a member of the Board of Directors and Editorial Board for the journal Pharmacotherapy. He has won several teaching awards, most recently was the recipient of the Doctor of Pharmacy Class of 2009’s Outstanding Instructor Award in May of 2008.
PROGRAM CHAIR:
Click the plus sign to see more detailed information about each speaker.
Dr. Saseen is an Associate Professor of Clinical Pharmacy and Family Medicine at the University of Colorado Denver. He is a Board Certified Pharmacotherapy Specialist with added qualifications in cardiology, is certified as a Clinical Lipid Specialist, and is a Fellow of the American College of Clinical Pharmacy. Dr. Saseen received both his B.S. pharmacy degree and PharmD degree from the State University of New York at Buffalo and then completed an ambulatory care research fellowship at the University of Illinois at Chicago. In his current position, Dr. Saseen practices as a clinical pharmacy specialist at University of Colorado’s Family Medicine Center, and educates pharmacy and medical students. His research and other scholarly endeavors focus on cardiovascular pharmacotherapy. Dr. Saseen is on the board of regents for the American College of Clinical Pharmacy, is a member of the Board of Directors for the National Lipid Association’s Accreditation Council for Clinical Lipidology, and is a member of the Board of Directors and Editorial Board for the journal Pharmacotherapy. He has won several teaching awards, most recently was the recipient of the Doctor of Pharmacy Class of 2009’s Outstanding Instructor Award in May of 2008.
Describe the effectiveness of available treatment options for the management of osteoarthritis.
Identify similarities and differences among the available biologic disease-modifying antirheumatic drugs (DMARDs) used to treat patients with rheumatoid arthritis.
List at least two long-term toxicities associated with the chronic use of nonsteroidal anti-inflammatory drugs (NSAIDs) and identify management strategies.
Summarize the role in therapy of disease-modifying antirheumatic drugs (DMARDs) including biologic agents, in the management of rheumatoid arthritis.